The study included about 35,000 patients who were initiated on SGLT2 inhibitors or DPP inhibitors between 2014 and 2020; the results showed that the administration of SGLT2 inhibitors was associated with a decreased risk of urinary tract infections and an increased risk of genital bacterial infections compared with DPP inhibitors, while there was no significant association with soft tissue infections [34]. The gene discussed is SLC5A2; the disease is urinary tract infection.